Description:
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have
a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary
objective of the study is to determine a recommended phase 2 dose (RP2D) of KRT 232 in
combination with ruxolitinib.
Title
- Brief Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
- Official Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Clinical Trial IDs
- ORG STUDY ID:
KRT-232-109
- NCT ID:
NCT04485260
Conditions
Interventions
Drug | Synonyms | Arms |
---|
KRT-232 | | Part A, Arm 1, Cohort 1 |
Ruxolitinib | Jakafi, Jakavi | Part A, Arm 1, Cohort 1 |
Purpose
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have
a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary
objective of the study is to determine a recommended phase 2 dose (RP2D) of KRT 232 in
combination with ruxolitinib.
Trial Arms
Name | Type | Description | Interventions |
---|
Part A, Arm 1, Cohort 1 | Experimental | KRT-232 by mouth once daily for Days 1-7, off treatment for Days 8-28 (28 day cycle) | |
Part A, Arm 2, Cohort 1 | Experimental | KRT-232 by mouth once daily for Days 1-5, off treatment for Days 6-28 (28 day cycle) | |
Eligibility Criteria
Inclusion Criteria:
- Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating
physician according to the World Health Organization (WHO)
- Treatment with ruxolitinib for ≥18 weeks prior to study entry, and on a stable dose of
ruxolitinib in the 8 weeks prior to study entry
- Spleen ≥5 cm palpable below the LLCM or ≥450 cm3 by MRI or CT
- Patients must have at least 2 symptoms with a score of at least 1 on the MFSAF v4.0
- ECOG performance status of 0 to 2
Exclusion Criteria:
- Patients who are positive for TP53 mutations
- Documented disease progression or clinical deterioration any time while on ruxolitinib
treatment
- Patients who have had a documented spleen response to ruxolitinib.
- Prior splenectomy
- Prior MDM2 inhibitor therapy or p53-directed therapy
Maximum Eligible Age: | 99 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | To determine the KRT-232 RP2D in combination with ruxolitinib |
Time Frame: | 15 months |
Safety Issue: | |
Description: | Dose limiting toxicities will be used to establish the MTD of KRT-232 in combination with ruxolitinib. Subsequently, RP2D will be based on safety and efficacy data of the combination. |
Secondary Outcome Measures
Measure: | To determine spleen response |
Time Frame: | 43 months |
Safety Issue: | |
Description: | The proportion of subjects achieving ≥35% SVR at any time point from Baseline while on study, as assessed by MRI (or by CT scan for applicable subjects) |
Measure: | To determine the change in Total Symptom Score (TSS) based Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) |
Time Frame: | 43 months |
Safety Issue: | |
Description: | The percentage change in TSS as measured by the MFSAF v4.0 at any time point from Baseline while on study |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Kartos Therapeutics, Inc. |
Last Updated
April 6, 2021